EP1883395A4 - Lipid construct for delivery of interferon to a mammal - Google Patents

Lipid construct for delivery of interferon to a mammal

Info

Publication number
EP1883395A4
EP1883395A4 EP06770516A EP06770516A EP1883395A4 EP 1883395 A4 EP1883395 A4 EP 1883395A4 EP 06770516 A EP06770516 A EP 06770516A EP 06770516 A EP06770516 A EP 06770516A EP 1883395 A4 EP1883395 A4 EP 1883395A4
Authority
EP
European Patent Office
Prior art keywords
interferon
mammal
delivery
lipid construct
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06770516A
Other languages
German (de)
French (fr)
Other versions
EP1883395A2 (en
Inventor
John R Lau
W Blair Geho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Technology Inc
Original Assignee
SDG Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/384,575 external-priority patent/US20070218117A1/en
Application filed by SDG Technology Inc filed Critical SDG Technology Inc
Publication of EP1883395A2 publication Critical patent/EP1883395A2/en
Publication of EP1883395A4 publication Critical patent/EP1883395A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP06770516A 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal Withdrawn EP1883395A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US11/384,575 US20070218117A1 (en) 2006-03-20 2006-03-20 Supra molecular construct for delivery of interferon to a mammal
PCT/US2006/019118 WO2006127360A2 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal

Publications (2)

Publication Number Publication Date
EP1883395A2 EP1883395A2 (en) 2008-02-06
EP1883395A4 true EP1883395A4 (en) 2012-07-04

Family

ID=37452604

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06770516A Withdrawn EP1883395A4 (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal

Country Status (6)

Country Link
EP (1) EP1883395A4 (en)
JP (1) JP2008542270A (en)
KR (1) KR20080042045A (en)
AU (1) AU2006249479A1 (en)
CA (1) CA2609376A1 (en)
WO (1) WO2006127360A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583652A (en) * 2007-08-03 2012-06-29 Biotron Ltd Hepatitis c antiviral compositions and methods
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
EP2235199A1 (en) * 2007-12-17 2010-10-06 Lux Innovate Limited Compositions and methods for maintenance of fluid conducting and containment systems
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
CN111690539A (en) * 2020-07-07 2020-09-22 安徽农业大学 Screening and application of high-efficiency straw cellulose decomposition bacteria
CA3200366A1 (en) * 2020-11-27 2022-06-02 D&D Pharmatech Inc. Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
AU2021385222A1 (en) * 2020-11-27 2023-06-22 D&D Pharmatech Inc. Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
WO1996017596A1 (en) * 1994-12-08 1996-06-13 Novartis Ag Liposomal interferon hybrid compositions
US5891468A (en) * 1996-10-11 1999-04-06 Sequus Pharmaceuticals, Inc. Fusogenic liposome compositions and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
WO1996017596A1 (en) * 1994-12-08 1996-06-13 Novartis Ag Liposomal interferon hybrid compositions
US5891468A (en) * 1996-10-11 1999-04-06 Sequus Pharmaceuticals, Inc. Fusogenic liposome compositions and method

Also Published As

Publication number Publication date
WO2006127360A3 (en) 2008-01-10
JP2008542270A (en) 2008-11-27
WO2006127360A2 (en) 2006-11-30
AU2006249479A1 (en) 2006-11-30
KR20080042045A (en) 2008-05-14
CA2609376A1 (en) 2006-11-30
EP1883395A2 (en) 2008-02-06

Similar Documents

Publication Publication Date Title
EP1883394A4 (en) Lipid construct for delivery of insulin to a mammal
ZA200900028B (en) Improvements relating to pharmaceutical compositions
ZA200904445B (en) Cyclopamine analogs
EP1883395A4 (en) Lipid construct for delivery of interferon to a mammal
ZA200710056B (en) Lipid construct for delivery of interferon to a mammal
EP2033643A4 (en) Compressed preparation
IL197938A0 (en) Il-21 variants
GB0616834D0 (en) Improvements to vacuum cleaners
TWM300307U (en) Improved positioning structure of a light-guide
GB0621467D0 (en) Improvements relating to residues
IL207764A0 (en) Antibody to a purified enho1 peptide
EP2109454A4 (en) Glp-1 pharmaceutical compositions
GB0600299D0 (en) Way to go
LT1883394T (en) Lipid construct for delivery of insulin to a mammal
TWI318598B (en) Mold structure
PL379202A1 (en) Candle in a shield
GB0607492D0 (en) Improvements to pumps
GB0602393D0 (en) Improvements to combustion
GB0605505D0 (en) Improvements to loudspeakers
GB0623613D0 (en) Improvements relating to barbecues
GB2423802B (en) Improvements relating to vacuum-brake-boosters
ZA200904725B (en) GLP-1 Pharmaceutical compositions
GB0607689D0 (en) Improvements relating to gas production
GB0607648D0 (en) Improvements relating to gas production
GB0621288D0 (en) Improvements relating to display devices

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20080110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20080222BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1118006

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20120601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20120525BHEP

Ipc: A61K 38/21 20060101ALI20120525BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1118006

Country of ref document: HK